

Other; specify ___

☐ Immunodeficiency-associated lymphoproliferative disorder (incl. PTLD)

EBMT	EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry:	Treatment Type
	LYMPHO	DMAS
	DISEA	SE
	te this form only if this diagnosis was the indicati nanual for further information.	on for the HCT/CT or if it was specifically requested.
Date of diagn	osis: / / (YYYY/MM/DD)	
Classification	ı:	
☐ B-cell lym	phoma (including Hodgkin and Non-Hodgkin lymphor	ma)
T-cell non	-Hodgkin lymphoma (NHL)	

Lymphomas_v2.0 1 of 10 2024-06-11



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	Othe
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//(YY	YY/MM/DI	D)

LYMPHOMAS B-cell lymphoma (including Hodkin and Non-Hodkin lymphoma)

DISEASE
Sub-Classification: Mature B-cell neoplasms
Splenic B-cell lymphomas and leukaemias
Splenic marginal zone lymphoma
Splenic diffuse red pulp small B-cell lymphoma
Lymphoplasmacytic lymphoma
☐ IgM-LPL/ Waldenström Macroglobulinaemia (WM) type
☐ Non-WM type LPL
☐ Marginal zone lymphoma
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Primary cutaneous marginal zone lymphoma
☐ Nodal marginal zone lymphoma
☐ Paediatric marginal zone lymphoma
☐ Follicular lymphoma
Classical follicular lymphoma (cFL)
Follicular large B-cell lym- phoma (FLBL)
FL with uncommon features (uFL)
De ediatrio terra falliandar husanbarra
Paediatric-type follicular lymphoma
Duodenal-type follicular lymphoma Cutanagus falliala captra lymphoma
Cutaneous follicle centre lymphoma
Mantle cell lymphoma
Mantle cell lymphoma
Leukaemic non-nodal mantle cell lymphoma



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//(YY	YY/MM/DI	D)

LYMPHOMAS B-cell lymphoma (including Hodkin and Non-Hodkin lymphoma)

DISEASE continued

Sub-Classification: Mature B-cell neoplasms
☐ Large B-cell lymphomas
☐ Diffuse large B-cell lymphoma (DLBCL), NOS
☐ Germinal centre B- cell-like subtype (GCB)
☐ Activated B-cell-like subtype (ABC)
☐ T-cell/histiocyte-rich large B-cell lymphoma
☐ Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC and BCL2 rearrangements
☐ ALK-positive large B-cell lymphoma
☐ Large B-cell lymphoma with IRF4 rearrangement
☐ High-grade B-cell lymphoma with 11q aberrations
☐ Lymphomatoid granulomatosis
☐ EBV-positive diffuse large B-cell lymphoma
☐ Diffuse large B-cell lymphoma associated with chronic inflammation
☐ Fibrin-associated large B-cell lymphoma
☐ Fluid overload-associated large B-cell lymphoma
Plasmablastic lymphoma
Primary large B-cell lymphoma of immune-privileged sites
Primary large B-cell lymphoma of the CNS
Primary large B-cell lymphoma of the vitreoretina
Primary large B-cell lymphoma of the testis
Primary cutaneous diffuse large B-cell lymphoma, leg type
☐ Intravascular large B-cell lymphoma
Primary mediastinal large B-cell lymphoma
☐ Mediastinal grey zone lymphoma
High-grade B-cell lymphoma, NOS
☐ Burkitt lymphoma ☐ EBV-positive BL
☐ EBV-positive BL
☐ KSHV/HHV8-associated B-cell lymphoid proliferations and lymphomas
Primary effusion lymphoma
☐ KSHV/HHV8-positive diffuse large B-cell lymphoma
☐ KSHV/HHV8-positive germinotropic lymphoproliferative disorder
☐ Hodgkin lymphoma ☐ Classic Hodgkin lymphoma
☐ Classic Hougkin lymphoma ☐ Nodular lymphocyte predominant Hodgkin lymphoma



High risk (4-5 score points)

☐ Not evaluated

Treatment Type	□ нст □ ст	☐ IST	☐ Other
Treatment Date _	//YY	YY/MM/DI	D)
		· L	Treatment Type HCT CT IST Treatment Date/_/ (YYYY/MM/DI

DISEASE continued						
Transformation of indolent B-cell lymphoma: No Yes (If not reported yet, complete respective non-indication diagnosis form in addition to the current form) Unknown Parameters for international prognostic indices:						
Age at diagnosis:		years (this is calcul	ated automa	atically in t	he database)
LDH levels elevated:	□ No	Yes	☐ Not e	valuated		
Ann Arbor staging:			III	□IV	☐ Not	evaluated
ECOG performance state	us: 🔲 0	1	2	<u></u> 3	<u> </u>	☐ Not evaluated
> 1 extranodal site involv	ved: No	☐ Yes	☐ Not e	valuated		
> 4 nodal sites involved:	☐ No	☐ No ☐ Yes ☐ Not evaluated				
Haemoglobin < 120g/L:	aemoglobin < 120g/L:					
White Blood Cell count:		_ x 10 ⁹ /L	☐ Not e	valuated		
CNS Involvement:	☐ No	☐ Yes	☐ Not e	valuated		
Final score: (only for patients with LBCL (except Primary large B-cell lymphoma of immune-privileged sites), Mantle cell lymphoma, Follicular lymphoma, Waldenstrom macroglobulinaemia)						
IPI: (for LBCL (except Primary large B-cell lymphoma of immune-privileged sites) and FLBL)	MIPI: (for Mantle cell lympho	oma)	FLIPI: (for Follicular ly FLBL))	/mphoma (exce	ept (for Wa	M: Ildenstrom macroglobulinaemia)
Low risk (0-1 score points) Low-intermediate risk (2 score points) High-intermediate risk	☐ Low risk ☐ Intermediate ri ☐ High risk	isk	Low risl	diate risk	□ (0 □ In (2	ow risk -1 score points except age > 65) termediate risk score points OR age > 65) igh risk
(3 score points)	☐ Not evaluated	Ī	☐ Not eva	luated	_ (3	-5 score points)

□ Not evaluated



	Patient Number in EBMT Registry:	Treatment Date _	/(Y	YYY/MM/D	D)
IT	EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN):	Treatment Type	□ нст □ ст	☐ IST	Other

CHROMOSOME ANALYSIS

Please complete chromosome analysis section only for patients with the following types of B-cell NHL:

	ma oglobulinaemia (LPL with monoclonal IgM) Intermediate DLBCL/BL and all LBCL)		
(Describe results of the r	done before HCT/CT treatment: most recent complete analysis)		
□ No			
☐ Yes: Ou ☐ Unknown	tput of analysis: Separate abnormalities	☐ Full karyotype	
If chromosome analy What were the resu			
□ Normal			
Abnormal: numbe	er of abnormalities present:		
☐ Failed			
Date of chromosom	ne analysis:: / / (YYYY/MM/DD)] Unknown	
For abnormal results, in lymphoma diagnosed).	dicate below whether the abnormalities were abse	nt, present or not ev	valuated (according to the type
Mantle cell lymphoma	del(17p)	☐ Absent	☐ Present ☐ Not evaluate
or Waldenstrom macro- globulinaemia	FISH	used: No	Yes
	t(2;8)	☐ Absent	☐ Present ☐ Not evaluate
Burkitt lymphoma or all	t(8;14)	Absent	☐ Present ☐ Not evaluate
LBCL	t(8;22)	Absent	☐ Present ☐ Not evaluate
	t(14;18)	Absent	☐ Present ☐ Not evaluate
All above mentioned B-cell lymphomas	Other chromosome abnormalities; specify:	Absent	Present

2024-06-11

Transcribe the complete karyotype: _____

EBMT Hospital	entre Identification Code (CIC): Unique Patient Number (UPN): Number in EBMT Registry:] HCT	
	MOLECU	LAR MARKER ANALYSIS	3		
 Mantle cell lympho 	cular marker analysis section on ma BL) or Intermediate DLBCL/BL an		ng types of	f B-cell NHL:	
	alysis done before HCT/CT trea e most recent complete analysis)				
	rker analysis (if tested)::	,	Unkno		
Indicate below whether	the markers were absent, preso	ent or not evaluated, accordin	ng to the typ	pe of lymphor	na diagnosed.
Mantle cell lymphoma	TP53 mutation		Absent	☐ Present	☐ Not evaluated
Burkitt lymphoma or all LBCL	MYC rearrangement		Absent	☐ Present	☐ Not evaluated
All LBCL	BCL2 rearrangement		Absent	Present	☐ Not evaluated
All all a secondanial	BCL6 rearrangement		Absent	Present	☐ Not evaluated
All above mentioned B-cell lymphomas	Other molecular markers; sp	pecify:] Absent	Present	
	IMM	UNOPHENOTYPING			
Mantle cell lymph	unophenotyping section only for oma (BL) or Intermediate DLBCL/BL al		oes of B-ce	ell NHL:	
	done before HCT/CT treatme e most recent complete analysis				
☐ Unknown					
_	notyping (if tested): /	_			
_	er the immunophenotypes were		ted, accord	ling to the typ	e of lymphoma
Mantle cell lymphoma	SOX 11		Absent	☐ Present	☐ Not evaluated
Burkitt lymphoma or all LBCL	мус		Absent	☐ Present	☐ Not evaluated

Lymphomas_v2.0 6 of 10 2024-06-11

☐ Absent ☐ Present ☐ Not evaluated

☐ Absent ☐ Present ☐ Not evaluated

☐ Absent ☐ Present

BCL2/IgH

 $Other\ immunophenotype;\ specify:$

BCL6

LBCL

All above mentioned

B-cell lymphomas



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST ☐ Other
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT Registry:	Treatment Date _	//YY	YY/MM/DD)

LYMPHOMAS T-cell non-Hodgkin lymphoma (NHL)

DISEASE
Sub-Classification: Mature T-cell & NK-cell neoplasms
☐ Mature T-cell and NK-cell leukaemias
☐ T-prolymphocytic leukaemia
☐ T-large granular lymphocytic leukaemia
☐ NK-large granular lymphocytic leukaemia
☐ Adult T-cell leukaemia/lymphoma
☐ Sezary syndrome
Aggressive NK-cell leukaemia
☐ Primary cutaneous T-cell lymphomas
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder
☐ Primary cutaneous acral CD8-positive lymphoproliferative disorder
☐ Mycosis fungoides
☐ Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: lymphomatoid papulosis
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
☐ Primary cutaneous gamma/delta T-cell lymphoma
☐ Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma
Primary cutaneous peripheral T-cell lymphoma, not otherwise specified
☐ Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas
☐ Indolent T-cell lymphoma of the gastrointestinal tract
☐ Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract
☐ Enteropathy-associated T-cell lymphoma
☐ Monomorphic epitheliotropic intestinal T-cell lymphoma
☐ Intestinal T-cell lymphoma not otherwise specified
☐ Hepatosplenic T-cell lymphoma
☐ Anaplastic large cell lymphomas
☐ ALK-positive anaplastic large cell lymphoma
☐ ALK-negative anaplastic large cell lymphoma
☐ Breast implant-associated anaplastic large cell lymphoma



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//(YY	YY/MM/DI	D)

LYMPHOMAS T-cell non-Hodgkin lymphoma (NHL)

DISEASE continued

,	Sub-Classification: Mature 1-cell & NK-cell Neoplasms
	□ Nodal T-follicular helper (TFH) lymphomas
	☐ Nodal TFH cell lymphoma, angioimmunoblastic-type
	☐ Nodal TFH cell lymphoma, follicular type
	☐ Nodal TFH cell lymphoma, not otherwise specified
	☐ Peripheral T-cell lymphoma, not otherwise specified
	☐ EBV-positive NK/T-cell lymphomas
	☐ EBV-positive nodal T- and NK-cell lymphoma
	☐ Extranodal NK/T-cell lymphoma
Ī	☐ EBV-positive T- and NK-cell lymphoid proliferations and lymphomas of childhood
	Severe mosquito bite allergy
	☐ Hydroa vacciniforme lymphoproliferative disorder
	Systemic chronic active EBV disease
	☐ Systemic FBV-positive T-cell lymphoma of childhood



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//(YY	YY/MM/DI	D)

LYMPHOMAS

Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)				
DISEASE				
Sub-Classification: Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)				
Lymphoproliferative disease associated with primary immune disorder				
Lymphoma associated with HIV infection				
Post-transplant lymphoproliferative disorder (PTLD)				
☐ Non-destructive PTLD				
☐ Plasmacytic hyperplasia PTLD				
☐ Infectious mononucleosis PTLD				
☐ Florid follicular hyperplasia PTLD				
☐ Polymorphic PTLD				
☐ Monomorphic PTLD				
☐ B-cell type				
☐ T-/NK-cell type				
☐ Classical Hodgkin lymphoma PTLD				
Other immunodeficiency-associated lymphoproliferative disorder				
Did the disease result from a previous solid organ transplant? □ No				
Yes: Date of transplant:/ (YYYY/MM/DD) Unknown				
Type of transplant: Renal				
Cardiac				
☐ Pulmonary				
Other; specify: Unknown				

Lymphomas_v2.0 9 of 10 2024-06-11



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date	//YY	YY/MM/DI	D)

		_	
	PREVIOUS THERAPIES (between diagnosis and HCT/CT	PREVIOUS THERAPIES (between diagnosis and HCT/CT)	
Previous	therapy lines before the HCT/CT:		
☐ No			
☐ Yes:	complete the "Treatment — non-HCT/CT/GT/IST" form		
☐ Unkn	own		